Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.

Arthritis Res Ther · 2018 · PMC6009058 · PMID 29921318

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Improvements in the fatigue domain of RAID, FACIT-F, and SF-36 VT were numerically greater with sarilumab than with adalimumab; however, between-group differences in FACIT-F, which was part of the hierarchy, did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.